MAcc CPA - Ocuphire Pharma Senior Finance
| OCUPDelisted Stock | USD 1.13 0.06 5.04% |
Executive
MAcc CPA is Senior Finance of Ocuphire Pharma
| Age | 43 |
| Phone | (248) 957-9024 |
| Web | https://www.ocuphire.com |
Ocuphire Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2135) % which means that it has lost $0.2135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3601) %, meaning that it created substantial loss on money invested by shareholders. Ocuphire Pharma's management efficiency ratios could be used to measure how well Ocuphire Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Ocuphire Pharma currently holds 4.04 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Ocuphire Pharma has a current ratio of 5.3, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Ocuphire Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Pablo MD | Kodiak Sciences | N/A | |
| Bruce MD | Mustang Bio | N/A | |
| Bobby Horn | Cognition Therapeutics | N/A | |
| Daniel MD | Transcode Therapeutics | 72 | |
| Ramiro MD | Eyepoint Pharmaceuticals | 41 | |
| Dario MD | Eyepoint Pharmaceuticals | 67 | |
| Robyn Hunter | Fortress Biotech | 62 | |
| David Jones | Eyepoint Pharmaceuticals | 56 | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Stephen Raillard | Kodiak Sciences | N/A | |
| Peter Carney | Mustang Bio | 37 | |
| Tarek Sallam | Rigel Pharmaceuticals | N/A | |
| Debra SPHR | Mustang Bio | N/A | |
| Greg MS | Mustang Bio | N/A | |
| Lisa MD | Rigel Pharmaceuticals | 58 | |
| John Doyle | Cognition Therapeutics | 47 | |
| Ron Esq | Eyepoint Pharmaceuticals | N/A | |
| Michael Louie | Kodiak Sciences | N/A | |
| David Santos | Rigel Pharmaceuticals | 61 | |
| Julie Patel | Rigel Pharmaceuticals | N/A | |
| Andrew Elnatan | Sellas Life Sciences | N/A | |
Management Performance
| Return On Equity | -0.36 | |||
| Return On Asset | -0.21 |
Ocuphire Pharma Leadership Team
Elected by the shareholders, the Ocuphire Pharma's board of directors comprises two types of representatives: Ocuphire Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ocuphire. The board's role is to monitor Ocuphire Pharma's management team and ensure that shareholders' interests are well served. Ocuphire Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ocuphire Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, VP Officer | ||
| Richard MBA, Interim Director | ||
| Bernhard MBA, Senior Secretary | ||
| MAcc CPA, Senior Finance | ||
| Erik Sims, Director Controller | ||
| MBA MD, CEO Director | ||
| Joseph MBA, Chief Officer | ||
| Ronil MS, Chief Officer | ||
| Daniela Oniciu, Chemistry RD | ||
| Mitchell Brigell, Head Strategy | ||
| Chris Ernst, Global Manufacturing | ||
| Bindu Manne, Head Commercialization | ||
| Ashwath Jayagopal, Chief Officer | ||
| Nirav CFA, Chief Officer | ||
| MBA MBA, CEO, Founder |
Ocuphire Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ocuphire Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (0.86) % | |||
| Operating Margin | (7.49) % | |||
| Current Valuation | (6.57 M) | |||
| Shares Outstanding | 26.2 M | |||
| Shares Owned By Insiders | 7.33 % | |||
| Shares Owned By Institutions | 10.44 % | |||
| Number Of Shares Shorted | 930.64 K | |||
| Price To Book | 0.86 X |
Pair Trading with Ocuphire Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ocuphire Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ocuphire Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Ocuphire Stock
Moving against Ocuphire Stock
| 0.83 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.75 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.69 | SSNLF | Samsung Electronics | PairCorr |
| 0.68 | CSCO | Cisco Systems Sell-off Trend | PairCorr |
| 0.67 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
The ability to find closely correlated positions to Ocuphire Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ocuphire Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ocuphire Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ocuphire Pharma to buy it.
The correlation of Ocuphire Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ocuphire Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ocuphire Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ocuphire Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |